Law360, New York (August 16, 2010, 7:12 PM ET) -- Eli Lilly & Co. has asked a federal judge to block Mylan Pharmaceuticals Inc., Apotex Inc. and other generics makers from releasing their own versions of attention deficit hyperactivity disorder drug Strattera until a federal appeals court rules on the validity of the patent covering the treatment.
In response to a ruling that the patent-in-suit is invalid due to lack of enablement, Lilly filed a motion Monday in the U.S. District Court for the District of New Jersey seeking a temporary injunction barring the seven remaining...
Lilly Seeks To Block Generic Strattera Amid Appeal
To view the full article, take a free trial now.
